Volume 9, Number 1, March 2019
|Number of page(s)||6|
|Published online||22 February 2019|
Association between colorectal cancer and thiazolidinediones administration in a case-control study
College of Medicine, Tzu Chi University, Hualien 970, Taiwan
2 Division of Hepatogastroenterology, Department of Internal Medicine, Taichung Tzu Chi Hospital, Taichung 427, Taiwan
3 College of Medicine, China Medical University, Taichung 404, Taiwan
4 Management Office for Health Data
5 Department of Family Medicine, China Medical University Hospital, Taichung 404, Taiwan
* Corresponding author. Department of Family Medicine, China Medical University Hospital, No. 2, Yu-De Road, Taichung 404, Taiwan. E-mail address: firstname.lastname@example.org (S.-W. Lai).
Accepted: 15 June 2018
Objectives: This study was designed to assess whether there was an association between colorectal cancer and thiazolidinediones use.
Methods: A population-based case-control study was performed using the database of the Taiwan National Health Insurance Program. The case group consisted of 20218 type 2 diabetic subjects aged 20 to 84 years with newly diagnosed colorectal cancer between 2000 and 2011. The date of a subject being diagnosed with colorectal cancer was defined as the index date. The control group consisted of 20218 randomly selected type 2 diabetic subjects aged 20 to 84 years without colorectal cancer between 2000 and 2011. A subject who had at least a prescription of thiazolidinediones before the index date was defined as “ever used”. A subject who did not have a prescription of thiazolidinediones before the index date was defined as “never used”. The odds ratio (OR) and 95% confidence interval (CI) was used to estimate the association between colorectal cancer and thiazolidinediones use by the multivariable logistic regression model.
Results: After adjustment for potential confounders, the odds of thiazolidinediones use in cases with colorectal cancer were lower than the odds of thiazolidinediones use in subjects without colorectal cancer (adjusted OR 0.94, 95% CI 0.89-0.99).
Conclusions: The odds of thiazolidinediones use in cases with colorectal cancer were lower than subjects without colorectal cancer. A prospective study is required to test whether thiazolidinediones use has a protective effect against colorectal cancer.
Key words: Case-control study / Colorectal cancer / Thiazolidinediones / Taiwan National Health Insurance Program
© Author(s) 2019. This article is published with open access by China Medical University
Open Access This article is distributed under terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided original author(s) and source are credited.